KRAS and lung carcinoma: This finding aligns with current research on pharmacological inhibition of MAPK pathway genes (i.e., BRAF, KRAS, and MEK1/2) for lung cancer treatment, highlighting the clinical relevance of altered 5hmC levels in these genes [53].